# Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

> **NCT03911219** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 154 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer
- Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

## Interventions

- **OTHER:** eHealth system support for symptom management via CANKADO

## Key facts

- **NCT ID:** NCT03911219
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-10
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2021-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911219, "Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03911219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*